Morel D, Bannwarth B, Vinçon G, Penouil F, Elouaer-Blanc L, Aparicio M, Potaux L
Service de Néphrologie, Hôpital Pellegrin-Tripode, CHU de Bordeaux, France.
Fundam Clin Pharmacol. 1993;7(3-4):167-70. doi: 10.1111/j.1472-8206.1993.tb00231.x.
The influence of a 7-day course of 40 mg famotidine administered orally on the pharmacokinetics of ciclosporine A at steady-state has been investigated in 10 renal transplant patients. Famotidine did not appear to significantly alter the pharmacokinetics of ciclosporine A. This might be ascribed to the limited potential of famotidine for inhibiting microsomal enzyme function. Moreover, plasma creatinine concentrations and creatinine clearance remained stable. Our results suggest that famotidine has no noticeable interaction with ciclosporine A.
在10名肾移植患者中研究了口服40毫克法莫替丁，疗程7天，对环孢素A稳态药代动力学的影响。法莫替丁似乎并未显著改变环孢素A的药代动力学。这可能归因于法莫替丁抑制微粒体酶功能的潜力有限。此外，血浆肌酐浓度和肌酐清除率保持稳定。我们的结果表明，法莫替丁与环孢素A之间没有明显的相互作用。
